je.st
news
Addition Of Amgen Drug Boosts Benefits In Relapsed Myeloma: Study
2014-12-08 09:04:12| Biotech - Topix.net
Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial. Patients with the blood cancer who received the Kyprolis regimen for 18 months also had a longer duration of response and reported better health-related quality of life, data presented on Saturday showed.
Tags: addition
study
benefits
drug
Category:Biotechnology and Pharmaceuticals